Skip to main content

HIV in Low and Middle-Income Countries: Addressing scientific gaps

Thematic Series

Edited by 
Ritu Gaur, South Asian University, New Delhi, India    
Thumbi Ndung’u, Africa Health Research Institute, Durban, South Africa 

New Content Item   

Over the past four decades, significant scientific progress has been made in our understanding of the modes of transmission, virus life cycle, host immune responses to the virus and viral adaptation to these immune responses. The scientific knowledge generated has led to the development of: reliable diagnostic tests; biomedical prevention strategies; and effective treatment options that contributed to the notable decline in HIV/AIDS related deaths and HIV incidence. However, HIV/AIDS remains the most significant public health challenge globally and is disproportionately affecting the low- and middle-income countries of the world. 

Two human immunodeficiency viruses exist, HIV-1 and HIV-2 that represent two separate independent zoonotic transmissions of simian immunodeficiency viruses from non-human primates to humans. HIV-1 has expanded most efficiently globally and is responsible for the vast majority of infections. HIV-1 exists as different groups, M, O, N and P. Group M is the dominant group globally and it can be subdivided into 10 subtypes and circulating recombinant forms. These subtypes are unevenly distributed worldwide and there is evidence that they have distinct dynamics of spread, are associated with differences in the rate of clinical disease progression and have distinct biological properties. 

Considering the disproportionate public health impact of HIV/AIDS in low- and middle-income countries and the uneven spread of HIV subtypes worldwide, this thematic series published in Retrovirology will emphasize the scientific gaps in HIV/AIDS research that are relevant to the epidemic in these settings. The series will highlight scientific challenges in understanding HIV diversity worldwide, HIV immunopathogenesis research relevant to the developing world and basic biology research that emphasizes the HIV-1 strains that predominate in low- and middle-income countries. The series will also discuss how these scientific findings can be translated to improve the prevention, treatment, cure and eradication of HIV, particularly in communities where these interventions are urgently needed. 

Submission instructions

Before submitting your manuscript, please ensure you have carefully read the submission guidelines for Retrovirology.

The complete manuscript should be submitted through the journal submission system.

To ensure that you submit to the correct thematic series please select this thematic series in the drop-down menu upon submission.

Deadline for submissions: 31 December 2021

View all collections in Retrovirology.

Back to Retrovirology homepage

  1. Bone marrow stromal antigen 2 (BST-2) also known as Tetherin (CD317/HM1.24), is a host restriction factor that blocks the release of HIV-1 virions from infected cells. Previous studies reported that BST-2 gene...

    Authors: Hlelolwenkosi Mlimi, Kewreshini K. Naidoo, Jenniffer Mabuka, Thumbi Ndung’u and Paradise Madlala
    Citation: Retrovirology 2022 19:3
  2. Our understanding of the peripheral human immunodeficiency virus type 1 (HIV-1) reservoir is strongly biased towards subtype B HIV-1 strains, with only limited information available from patients infected with...

    Authors: Samira Joussef-Piña, Immaculate Nankya, Sophie Nalukwago, Joy Baseke, Sandra Rwambuya, Dane Winner, Fred Kyeyune, Keith Chervenak, Bonnie Thiel, Robert Asaad, Curtis Dobrowolski, Benjamin Luttge, Blair Lawley, Cissy M. Kityo, W. Henry Boom, Jonathan Karn…
    Citation: Retrovirology 2022 19:1
  3. We observe the emergence of several promoter-variant viral strains in India during recent years. The variant viral promoters contain additional copies of transcription factor binding sites present in the viral...

    Authors: Haider Ali, Disha Bhange, Kavita Mehta, Yuvrajsinh Gohil, Harshit Kumar Prajapati, Siddappa N. Byrareddy, Shilpa Buch and Udaykumar Ranga
    Citation: Retrovirology 2021 18:27
  4. CRF55_01B is a newly identified HIV-1 circulating recombinant form originated from MSM in China. However, its impact on the disease progression and transmission risk has not been investigated. This study aimed...

    Authors: Lan Wei, Hao Li, Xing Lv, Chenli Zheng, Guilian Li, Zhengrong Yang, Lin Chen, Xiaoxu Han, Huachun Zou, Yanxiao Gao, Jinquan Cheng, Hui Wang and Jin Zhao
    Citation: Retrovirology 2021 18:22
  5. HIV-1 persists in infected individuals despite years of antiretroviral therapy (ART), due to the formation of a stable and long-lived latent viral reservoir. Early ART can reduce the latent reservoir and is as...

    Authors: Sherazaan D. Ismail, Joshua Pankrac, Emmanuel Ndashimye, Jessica L. Prodger, Melissa-Rose Abrahams, Jamie F. S. Mann, Andrew D. Redd and Eric J. Arts
    Citation: Retrovirology 2021 18:21
  6. The potential use of the broadly neutralizing monoclonal antibodies (bnAbs) towards prophylaxis and treatment to HIV-1 is currently being explored. While a number of promising bnAbs have been discovered and a ...

    Authors: Ranajoy Mullick, Jyoti Sutar, Nitin Hingankar, Suprit Deshpande, Madhuri Thakar, Seema Sahay, Rajesh P. Ringe, Sampurna Mukhopadhyay, Ajit Patil, Shubhangi Bichare, Kailapuri G. Murugavel, Aylur K. Srikrishnan, Rajat Goyal, Devin Sok and Jayanta Bhattacharya
    Citation: Retrovirology 2021 18:12
  7. The HIV-1 epidemic in sub-Saharan Africa is heterogeneous with diverse unevenly distributed subtypes and regional differences in prevalence. Subtype-specific differences in disease progression rate and transmi...

    Authors: Omotayo Farinre, Kamini Gounder, Tarylee Reddy, Marcel Tongo, Jonathan Hare, Beth Chaplin, Jill Gilmour, Phyllis Kanki, Jaclyn K. Mann and Thumbi Ndung’u
    Citation: Retrovirology 2021 18:11
  8. Maturation inhibitors (MIs) potently block HIV-1 maturation by inhibiting the cleavage of the capsid protein and spacer peptide 1 (CA-SP1). Bevirimat (BVM), a highly efficacious first-in-class MI against HIV-1...

    Authors: Dibya Ghimire, Yuvraj KC, Uddhav Timilsina, Kriti Goel, T. J. Nitz, Carl T. Wild and Ritu Gaur
    Citation: Retrovirology 2021 18:9